Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NC410

Fusion protein · Antagonist of LAIR-1 (CD305) (LAIR1) · developed by NextCure

Phase 2 Most advanced trial
NXTC Developer
1 Registered trials

What is NC410?

NC410 is a fusion protein based on leukocyte-associated immunoglobulin-like receptor 2 (LAIR-2), a high-affinity collagen receptor. It binds collagen, blocking collagen binding to the inhibitory receptor LAIR-1 on T cells and dendritic cells. It is being studied in pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NextCure LAIR-2 fusion protein
Drug type
Fusion protein
Targets
LAIR-1 (CD305) (LAIR1), collagen (binding partner it blocks)
Mechanism
Antagonist of LAIR-1 (CD305) (LAIR1)
Pathways
LAIR-1-mediated immune suppression, T-cell activation, dendritic cell activity, cytotoxic T-lymphocyte anti-tumor response
Therapy area
Oncology
Developer
NextCure, Inc. (NXTC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
I8YLE03D8B

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06941857 Phase 2 Pancreatic Cancer Recruiting NXTC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic Cancer

Other drugs acting on LAIR1

More from NextCure

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NXTC page.

Follow NXTC, the company behind NC410

See NXTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NXTC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.